Akari Therapeutics’ Nomacopan Demonstrates Positive Early Safety and Efficacy in Phase I/II Clinical Study in Moderate-to-Severe Atopic Keraconjunctivitis (AKC)

NEXT STORY
Outlook on the Worldwide Anti-tuberculosis Therapeutics Market to 2024 – Driven by the Rising Incidence of MDR & XDR Cases in Developing Countries
PREV STORY
The World Market for Capnography Devices to 2026 – A $1.58 Billion Opportunity with Microstream Capnography Expected to Expand at the Fastest CAGR
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission

Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten ...

author_avatar
NASDAQ Market News

European Cleanroom Technology Market Size to Reach $1,701.8 Million by 2023: P&S Intelligence

Europe Cleanroom Technology Market by Product (Consumables [Safety {Gloves, Apparel}, Cleaning {Wipes, Disinfectants, Vacuum ...

author_avatar
NASDAQ Market News

VALNEVA Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

 Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate Phase 1 ...

author_avatar
NASDAQ Market News